Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||TP-1454 + unspecified CTLA4 antibody + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|TP-1454||TP1454|TP 1454||TP-1454 is a pyruvate kinase M2 (PKM2) activator, which may inhibit tumor cell viability and tumor growth, and enhance anti-tumor immune response in combination with other agents (Mol Cancer Ther December 1 2019 (18) (12 Supplement) B080).|
|unspecified CTLA4 antibody||experimental CTLA4 antibody|
|unspecified PD-1 antibody||Experimental PD-1 antibody||PD-L1/PD-1 antibody 63|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||TP-1454 + unspecified CTLA4 antibody + unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, TP-1454 combined with an anti-CTLA4 and an anti-PD1 antibody inhibited tumor growth and increased survival in a syngeneic mouse model of colorectal cancer (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B080).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|